EN
L-carnitine, L-propionyl carnitine and malondialdehyde levels of pediatric patients with solid tumor
Abstract
It is known that the production of free O2 radicals and oxidation products have a significant increase in patients with cancer. There are endogeneous protection systems in order to remove free O2 radicals. One of these endogeneous protection system is carnitine. Carnitine has an important role in muscle functions and in obtaining energy from the membranes of body cells.
This study aims to investigate the role of L-carnitine, L-propionyl carnitine and malondialdehyde (MDA) in antioxidant mechanism in children recently diagnosed with solid tumor. The study group were consisted from 57 children from 2 children's cancer centers (Gazi University Pediatrics Department and Sami Ulus Pediatrics Hospital) who were recently diagnosed with solid tumor and 45 healthy control. There was no significant difference in free carnitine and L-propionyl carnitine levels between patients with solid tumor and healthy controls. But, MDA levels were significantly higher in children with recently diagnosed solid tumor than in healthy controls.
Keywords
Details
Primary Language
English
Subjects
-
Journal Section
-
Authors
Publication Date
August 1, 2012
Submission Date
June 25, 2012
Acceptance Date
-
Published in Issue
Year 2012 Volume: 4 Number: 3
APA
Okur, A. (2012). L-carnitine, L-propionyl carnitine and malondialdehyde levels of pediatric patients with solid tumor. Journal of Pediatric Sciences, 4(3), 1-6. https://doi.org/10.17334/jps.77916
AMA
1.Okur A. L-carnitine, L-propionyl carnitine and malondialdehyde levels of pediatric patients with solid tumor. Journal of Pediatric Sciences. 2012;4(3):1-6. doi:10.17334/jps.77916
Chicago
Okur, Arzu. 2012. “L-Carnitine, L-Propionyl Carnitine and Malondialdehyde Levels of Pediatric Patients With Solid Tumor”. Journal of Pediatric Sciences 4 (3): 1-6. https://doi.org/10.17334/jps.77916.
EndNote
Okur A (September 1, 2012) L-carnitine, L-propionyl carnitine and malondialdehyde levels of pediatric patients with solid tumor. Journal of Pediatric Sciences 4 3 1–6.
IEEE
[1]A. Okur, “L-carnitine, L-propionyl carnitine and malondialdehyde levels of pediatric patients with solid tumor”, Journal of Pediatric Sciences, vol. 4, no. 3, pp. 1–6, Sept. 2012, doi: 10.17334/jps.77916.
ISNAD
Okur, Arzu. “L-Carnitine, L-Propionyl Carnitine and Malondialdehyde Levels of Pediatric Patients With Solid Tumor”. Journal of Pediatric Sciences 4/3 (September 1, 2012): 1-6. https://doi.org/10.17334/jps.77916.
JAMA
1.Okur A. L-carnitine, L-propionyl carnitine and malondialdehyde levels of pediatric patients with solid tumor. Journal of Pediatric Sciences. 2012;4:1–6.
MLA
Okur, Arzu. “L-Carnitine, L-Propionyl Carnitine and Malondialdehyde Levels of Pediatric Patients With Solid Tumor”. Journal of Pediatric Sciences, vol. 4, no. 3, Sept. 2012, pp. 1-6, doi:10.17334/jps.77916.
Vancouver
1.Arzu Okur. L-carnitine, L-propionyl carnitine and malondialdehyde levels of pediatric patients with solid tumor. Journal of Pediatric Sciences. 2012 Sep. 1;4(3):1-6. doi:10.17334/jps.77916